Home LiteratureArticle Details
PMID: 1622174 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Effect of glycerol monolaurate on bacterial growth and toxin production.

Antimicrobial agents and chemotherapy ·Vol. 36 ·No. 3 ·1992-03-00 ·Pages 626-31

Schlievert PM, Deringer JR, Kim MH, Projan SJ, Novick RP

Abstract

Glycerol monolaurate (GML) is a naturally occurring surfactant that has potential use as an additive to tampons and wound dressings to reduce the incidence of certain bacterial toxin-mediated illnesses. In vitro studies were undertaken to evaluate the effect of GML on the growth of and toxin production by potentially pathogenic bacteria. GML inhibited the growth of clinical isolates of group A, B, F, and G streptococci at concentrations of 10 to 20 micrograms/ml. Exotoxin production, including that of pyrogenic exotoxins and hemolysins, was reduced by concentrations of GML that were below those inhibitory for growth as well as growth inhibitory. The growth of Staphylococcus aureus strains from patients with toxic shock syndrome and scalded skin syndrome was inhibited or delayed in the presence of 100 to 300 micrograms of GML per ml. Growth inhibition by GML could be overcome by the production of lipase. S. aureus elaboration of hemolysin, toxic shock syndrome toxin 1, and exfoliative toxin A was inhibited at GML concentrations below those necessary to inhibit growth. Results similar to those for S. aureus were obtained in tests of S. hominis. Escherichia coli growth and Salmonella minnesota growth were unaffected by GML, but an S. minnesota Re mutant was susceptible to growth-inhibitory activity. Endotoxin release into the medium from E. coli cells was also unaffected by GML, but the release or activity of E. coli hemolysin was increased by GML. Streptococcal pyrogenic endotoxin A production by an E. coli clone was not affectd by GML. These studies indicate that GML is effective in blocking or delaying the production of exotoxins by pathogenic gram-positive bacteria.

MeSH Terms
Glycerides/pharmacology Gram-Negative Bacteria/drug effects,growth & development Gram-Positive Bacteria/drug effects,growth & development Laurates/pharmacology Lipase/metabolism Monoglycerides Staphylococcus aureus/drug effects,enzymology,growth & development Toxins, Biological/biosynthesis Zinc/pharmacology
Chemicals
Glycerides Laurates Monoglycerides Toxins, Biological monolaurin Lipase Zinc
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Schlievert P M
Department of Microbiology, University of Minnesota Medical School, Minneapolis 55455.
Deringer J R
Kim M H
Projan S J
Novick R P
References (29)
29 references, click to expand
  1. Production of toxic shock syndrome-like illness in rabbits by Staphylococcus aureus D4508: association with enterotoxin A.
    Infect Immun. 1990 Jul;58(7):2067-70 PMID: 2365451
  2. Nucleotide sequence of the streptococcal pyrogenic exotoxin type B gene and relationship between the toxin and the streptococcal proteinase precursor.
    J Bacteriol. 1990 Aug;172(8):4536-42 PMID: 2198264
  3. A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots.
    Anal Biochem. 1984 Jan;136(1):175-9 PMID: 6424501
  4. Group A streptococcal phage T12 carries the structural gene for pyrogenic exotoxin type A.
    Mol Gen Genet. 1984;194(1-2):52-6 PMID: 6374381
  5. Variant postpartum toxic shock syndrome with probable intrapartum transmission to the neonate.
    Am J Obstet Gynecol. 1984 Apr 15;148(8):1074-9 PMID: 6711641
  6. Clindamycin-induced suppression of toxic-shock syndrome--associated exotoxin production.
    J Infect Dis. 1984 Mar;149(3):471 PMID: 6715902
  7. Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors.
    J Infect Dis. 1983 Feb;147(2):236-42 PMID: 6827140
  8. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome.
    J Infect Dis. 1981 Apr;143(4):509-16 PMID: 6972418
  9. Tri-state toxic-state syndrome study. I. Epidemiologic findings.
    J Infect Dis. 1982 Apr;145(4):431-40 PMID: 7069223
  10. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases.
    N Engl J Med. 1980 Dec 18;303(25):1436-42 PMID: 7432402
  11. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention.
    N Engl J Med. 1980 Dec 18;303(25):1429-35 PMID: 7432401
  12. Toxic-shock syndrome associated with phage-group-I Staphylococci.
    Lancet. 1978 Nov 25;2(8100):1116-8 PMID: 82681
  13. Purification and characterization of group A streptococcal pyrogenic exotoxin type C.
    Infect Immun. 1977 May;16(2):673-9 PMID: 324918
  14. Quantitative bacteriology of the vaginal flora.
    J Infect Dis. 1977 Aug;136(2):271-7 PMID: 894079
  15. Production of staphylococcal enterotoxins A, B, and C in colloidal dispersions.
    Appl Microbiol. 1973 May;25(5):825-33 PMID: 4197641
  16. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  17. Production of opacity in egg-yolk broth by Staphylococci from various sources.
    J Pathol Bacteriol. 1953 Jul;66(1):205-10 PMID: 13109632
  18. Steady-state staphylococcal enterotoxin type C mRNA is affected by a product of the accessory gene regulator (agr) and by glucose.
    Infect Immun. 1991 Mar;59(3):955-62 PMID: 1997441
  19. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.
    Crit Rev Microbiol. 1990;17(4):251-72 PMID: 2206394
  20. The nucleotide and partial amino acid sequence of toxic shock syndrome toxin-1.
    J Biol Chem. 1986 Nov 25;261(33):15783-6 PMID: 3782090
  21. Molecular basis of bacterial outer membrane permeability.
    Microbiol Rev. 1985 Mar;49(1):1-32 PMID: 2580220
  22. Regulation of exoprotein gene expression in Staphylococcus aureus by agar.
    Mol Gen Genet. 1986 Jan;202(1):58-61 PMID: 3007938
  23. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS.
    Lancet. 1986 May 17;1(8490):1149-50 PMID: 2871397
  24. Clinical aspects and spectrum of illness of toxic shock syndrome: overview.
    Rev Infect Dis. 1989 Jan-Feb;11 Suppl 1:S1-7 PMID: 2522671
  25. Toxic shock syndrome caused by a strain of Staphylococcus aureus that produces enterotoxin C but not toxic shock syndrome toxin-1.
    Am J Dis Child. 1989 Jul;143(7):848-9 PMID: 2741860
  26. Toxic shock syndrome Staphylococcus aureus: effect of tampons on toxic shock syndrome toxin 1 production.
    Obstet Gynecol. 1984 Nov;64(5):666-71 PMID: 6436761
  27. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1.
    Infect Immun. 1987 May;55(5):1070-6 PMID: 3570455
  28. Importance of exfoliatin toxin A production by Staphylococcus aureus strains isolated from clustered epidemics of neonatal pustulosis.
    J Clin Microbiol. 1986 Jan;23(1):83-91 PMID: 3700612
  29. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates.
    Lancet. 1981 May 9;1(8228):1017-21 PMID: 6112412
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1992-03-00
Pages
626-31
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC190568
Subset
IM
Grants
NIAID NIH HHS · AI 22159 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]